The 'Biosimilars Insulin market' research report drafted by Brandessenceresearch.biz, elucidates relevant market and competitive insights as well as regional and consumer information. In a nutshell, the research study covers every pivotal aspect of this business sphere that influences the existing trends, profitability position, market share, market size, regional valuation, and business expansion plans of key players in the Biosimilars Insulin market.
Biosimilars is a biological product designed to have similar active properties to the one that has been previously licensed and has no clinically significant differences in terms of safety and effectiveness. Biosimilars insulin is a type of biosimilars where it is indistinguishable to the reference insulin product and is already been approved by FDA or licensed. The producers of biosimilars use the similar manufacturing techniques as of the patented product but not likely identical to that used by the patent holder. Due to increasing insulin manufacturers from the developed and developing countries, the patents for insulin formulations had neared expiry or were ended. This created a necessity to seek approvals on biosimilar insulin for the not yet established companies in the highly regulated markets such as Europe and United States. In 2014, The European Commission (EC) first granted insulin treatment through the biosimilars pathway to Eli Lilly and Company and Boehringer Ingelheim GmbH. Lilly/Boehringer Ingelheim developed a biosimilar insulin called “Insulin glargine” and was the fourth diabetes product which was approved from Lilly-Boehringer Ingelheim Alliance in Europe. Basaglar is the first “biosimilar” insulin product to be approved and launched in U.S. which was developed by the alliance of Lilly/Boehringer Ingelheim.
Increasing prevalence of Type I diabetes, higher cost of existing insulin drugs are expected to drive growth of insulin biosimilars market. Government authorities are also focusing on the approval of insulin biosimilars owing to substantial financial burden in terms of reimbursements. Recently, the U.S. FDA has approved new insulin glargine Basaglar, for type 1 and type 2 diabetes which is Biosimilar version of Sanofi’s basal insulin Lantus (insulin glargine). Additionally, Lilly and Boehringer Ingelheim's biosimilar insulin glargine has got approval through European Medicines Agency's (EMA's) Biosimilar pathway. Such ongoing approvals by the respective authorities are expected to drive the growth of insulin Biosimilar market. However, Insulin patent protection rights and strong retaliation from the branded manufactures has restricted the growth of insulin biosimilar development.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Biosimilars Insulin.
This report studies the global market size of Biosimilars Insulin, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Biosimilars Insulin sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
Eli Lilly
Boehringer Ingelheim
Merck
Pfizer
Biocon
Mylan
...
Market Segment by Product Type
Insulin Glargine Basaglar
Insulin Lantus
Market Segment by Application
Type I Diabetes
Type II Diabetes
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Biosimilars Insulin status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Biosimilars Insulin manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Biosimilars Insulin are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Interested in this report?
Get your sample now!
Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Major Manufacturers Covered in This Report
1.3 Market Segment by Type
1.3.1 Global Biosimilars Insulin Market Size Growth Rate by Type (2019-2025)
1.3.2 Insulin Glargine Basaglar
1.3.3 Insulin Lantus
1.4 Market Segment by Application
1.4.1 Global Biosimilars Insulin Market Share by Application (2019-2025)
1.4.2 Type I Diabetes
1.4.3 Type II Diabetes
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Biosimilars Insulin Market Size
2.1.1 Global Biosimilars Insulin Revenue 2014-2025
2.1.2 Global Biosimilars Insulin Sales 2014-2025
2.2 Biosimilars Insulin Growth Rate by Regions
2.2.1 Global Biosimilars Insulin Sales by Regions 2014-2019
2.2.2 Global Biosimilars Insulin Revenue by Regions 2014-2019
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
3 Market Share by Manufacturers
3.1 Biosimilars Insulin Sales by Manufacturers
3.1.1 Biosimilars Insulin Sales by Manufacturers 2014-2019
3.1.2 Biosimilars Insulin Sales Market Share by Manufacturers 2014-2019
3.2 Revenue by Manufacturers
3.2.1 Biosimilars Insulin Revenue by Manufacturers (2014-2019)
3.2.2 Biosimilars Insulin Revenue Share by Manufacturers (2014-2019)
3.2.3 Global Biosimilars Insulin Market Concentration Ratio (CR5 and HHI)
3.3 Biosimilars Insulin Price by Manufacturers
3.4 Key Manufacturers Biosimilars Insulin Plants/Factories Distribution and Area Served
3.5 Date of Key Manufacturers Enter into Biosimilars Insulin Market
3.6 Key Manufacturers Biosimilars Insulin Product Offered
3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Sales and Revenue for Each Type
4.1.1 Insulin Glargine Basaglar Sales and Revenue (2014-2019)
4.1.2 Insulin Lantus Sales and Revenue (2014-2019)
4.2 Global Biosimilars Insulin Sales Market Share by Type
4.3 Global Biosimilars Insulin Revenue Market Share by Type
4.4 Biosimilars Insulin Price by Type
5 Market Size by Application
5.1 Overview
5.2 Global Biosimilars Insulin Sales by Application
6 United States
6.1 United States Biosimilars Insulin Breakdown Data by Company
6.2 United States Biosimilars Insulin Breakdown Data by Type
6.3 United States Biosimilars Insulin Breakdown Data by Application
7 European Union
7.1 European Union Biosimilars Insulin Breakdown Data by Company
7.2 European Union Biosimilars Insulin Breakdown Data by Type
7.3 European Union Biosimilars Insulin Breakdown Data by Application
8 China
8.1 China Biosimilars Insulin Breakdown Data by Company
8.2 China Biosimilars Insulin Breakdown Data by Type
8.3 China Biosimilars Insulin Breakdown Data by Application
9 Rest of World
9.1 Rest of World Biosimilars Insulin Breakdown Data by Company
9.2 Rest of World Biosimilars Insulin Breakdown Data by Type
9.3 Rest of World Biosimilars Insulin Breakdown Data by Application
9.4 Rest of World Biosimilars Insulin Breakdown Data by Countries
9.4.1 Rest of World Biosimilars Insulin Sales by Countries
9.4.2 Rest of World Biosimilars Insulin Revenue by Countries
9.4.3 Japan
9.4.4 Korea
9.4.5 India
9.4.6 Southeast Asia
10 Company Profiles
10.1 Eli Lilly
10.1.1 Eli Lilly Company Details
10.1.2 Company Description and Business Overview
10.1.3 Sales, Revenue and Market Share of Biosimilars Insulin
10.1.4 Biosimilars Insulin Product Introduction
10.1.5 Eli Lilly Recent Development
10.2 Boehringer Ingelheim
10.2.1 Boehringer Ingelheim Company Details
10.2.2 Company Description and Business Overview
10.2.3 Sales, Revenue and Market Share of Biosimilars Insulin
10.2.4 Biosimilars Insulin Product Introduction
10.2.5 Boehringer Ingelheim Recent Development
10.3 Merck
10.3.1 Merck Company Details
10.3.2 Company Description and Business Overview
10.3.3 Sales, Revenue and Market Share of Biosimilars Insulin
10.3.4 Biosimilars Insulin Product Introduction
10.3.5 Merck Recent Development
10.4 Pfizer
10.4.1 Pfizer Company Details
10.4.2 Company Description and Business Overview
10.4.3 Sales, Revenue and Market Share of Biosimilars Insulin
10.4.4 Biosimilars Insulin Product Introduction
10.4.5 Pfizer Recent Development
10.5 Biocon
10.5.1 Biocon Company Details
10.5.2 Company Description and Business Overview
10.5.3 Sales, Revenue and Market Share of Biosimilars Insulin
10.5.4 Biosimilars Insulin Product Introduction
10.5.5 Biocon Recent Development
10.6 Mylan
10.6.1 Mylan Company Details
10.6.2 Company Description and Business Overview
10.6.3 Sales, Revenue and Market Share of Biosimilars Insulin
10.6.4 Biosimilars Insulin Product Introduction
10.6.5 Mylan Recent Development
11 Value Chain and Sales Channels Analysis
11.1 Value Chain Analysis
11.2 Sales Channels Analysis
11.2.1 Biosimilars Insulin Sales Channels
11.2.2 Biosimilars Insulin Distributors
11.3 Biosimilars Insulin Customers
12 Market Forecast
12.1 Global Biosimilars Insulin Sales and Revenue Forecast 2019-2025
12.2 Global Biosimilars Insulin Sales Forecast by Type
12.3 Global Biosimilars Insulin Sales Forecast by Application
12.4 Biosimilars Insulin Forecast by Regions
12.4.1 Global Biosimilars Insulin Sales Forecast by Regions 2019-2025
12.4.2 Global Biosimilars Insulin Revenue Forecast by Regions 2019-2025
12.5 United States Market Forecast
12.6 European Union Market Forecast
12.7 China Market Forecast
12.8 Rest of World
12.8.1 Japan
12.8.2 Korea
12.8.3 India
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
List of Tables and Figures
Figure Biosimilars Insulin Product Picture
Table Biosimilars Insulin Key Market Segments
Table Major Manufacturers Biosimilars Insulin Covered in This Report
Table Global Biosimilars Insulin Market Size Growth Rate by Type 2019-2025 (K MT) & (Million US$)
Figure Global Biosimilars Insulin Sales Market Shar by Type 2014-2025
Figure Insulin Glargine Basaglar Figures
Table Major Manufacturers of Insulin Glargine Basaglar
Figure Insulin Lantus Figures
Table Major Manufacturers of Insulin Lantus
Table Global Biosimilars Insulin Market Share by Application 2019-2025 (K MT)
Figure Type I Diabetes Use Case
Figure Type II Diabetes Use Case
Figure Biosimilars Insulin Report Years Considered
Figure Global Biosimilars Insulin Market Size 2014-2025 (Million US$)
Figure Global Biosimilars Insulin Sales 2014-2019 (K MT)
Table Global Biosimilars Insulin Market Size by Regions 2014-2019 (K MT) & (Million US$)
Table Global Biosimilars Insulin Sales by Regions 2014-2019 (K MT)
Table Global Biosimilars Insulin Sales Market Share by Regions 2014-2019
Figure Global Biosimilars Insulin Sales Market Share by Regions 2014-2019
Figure Global Biosimilars Insulin Sales Market Share by Regions in 2019
Table Global Biosimilars Insulin Revenue by Regions 2014-2019 (Million US$)
Table Global Biosimilars Insulin Revenue Market Share by Regions 2014-2019
Figure Global Biosimilars Insulin Revenue Market Share by Regions 2014-2019
Figure Global Biosimilars Insulin Revenue Market Share by Regions in 2019
Table Market Top Trends
Table Global Biosimilars Insulin Sales by Manufacturers (2014-2019) (K MT)
Table Global Biosimilars Insulin Sales Share by Manufacturers (2014-2019)
Figure Global Biosimilars Insulin Sales Share by Manufacturers in 2019
Table Biosimilars Insulin Revenue by Manufacturers (2014-2019) (Million USD)
Table Biosimilars Insulin Revenue Share by Manufacturers (2014-2019)
Figure Biosimilars Insulin Value Share by Manufacturers in 2019
Table Global Biosimilars Insulin Manufacturers Market Concentration Ratio (CR5 and HHI)
Table Key Manufacturers Biosimilars Insulin Price (2014-2019) (USD/MT)
Table Key Manufacturers Biosimilars Insulin Plants/Factories Distribution
Table Key Manufacturers Biosimilars Insulin Area Served
Table Date of Key Manufacturers Enter into Biosimilars Insulin Market
Table Key Manufacturers Biosimilars Insulin Product Type
Table Mergers & Acquisitions, Expansion Plans
Table Global Insulin Glargine Basaglar Sales and Revenue (2014-2019) (K MT) & (Million US$)
Table Global Insulin Lantus Sales and Revenue (2014-2019) (K MT) & (Million US$)
Table Global Biosimilars Insulin Sales by Type (2014-2019) (K MT)
Table Global Biosimilars Insulin Sales Share by Type (2014-2019)
Figure Global Biosimilars Insulin Sales Market Share by Type (2014-2019)
Figure Global Biosimilars Insulin Sales Market Share by Type in 2018
Table Global Biosimilars Insulin Revenue by Type (2014-2019) (Million US$)
Table Global Biosimilars Insulin Revenue Share by Type (2014-2019)
Figure Global Biosimilars Insulin Revenue Market Share by Type (2014-2019)
Figure Global Biosimilars Insulin Revenue Market Share by Type in 2018
Table Biosimilars Insulin Price by Type 2014-2019 (USD/MT)
Table Global Biosimilars Insulin Sales by Application (2014-2019) (K MT)
Table Global Biosimilars Insulin Sales Share by Application (2014-2019)
Figure Global Sales Biosimilars Insulin Market Share by Application (2014-2019)
Figure Global Sales Biosimilars Insulin Market Share by Application (2014-2019)
Figure United States Biosimilars Insulin Sales Growth Rate 2014-2019 (K MT)
Figure United States Biosimilars Insulin Revenue Growth Rate 2014-2019 (Million US$)
Table United States Biosimilars Insulin Sales by Company (2014-2019) (K MT)
Table United States Biosimilars Insulin Sales Market Share by Company (2014-2019)
Figure United States Biosimilars Insulin Sales Market Share by Company in 2019
Table United States Biosimilars Insulin Sales by Type (2014-2019) (K MT)
Table United States Biosimilars Insulin Sales Market Share by Type (2014-2019)
Figure United States Biosimilars Insulin Market Share by Type in 2019
Table United States Biosimilars Insulin Sales by Application (2014-2019) (K MT)
Table United States Biosimilars Insulin Sales Market Share by Application (2014-2019)
Figure United States Biosimilars Insulin Market Share by Application in 2019
Figure European Union Biosimilars Insulin Sales Growth Rate 2014-2019 (K MT)
Figure European Union Biosimilars Insulin Revenue Growth Rate 2014-2019 (Million US$)
Table European Union Biosimilars Insulin Sales by Company (2014-2019) (K MT)
Table European Union Biosimilars Insulin Sales Market Share by Company (2014-2019)
Figure European Union Biosimilars Insulin Sales Market Share by Company in 2019
Table European Union Biosimilars Insulin Sales by Type (2014-2019) (K MT)
Table European Union Biosimilars Insulin Sales Market Share by Type (2014-2019)
Figure 2018 European Union Biosimilars Insulin Market Share by Type
Table European Union Biosimilars Insulin Sales by Application (2014-2019) (K MT)
Table European Union Biosimilars Insulin Sales Market Share by Application (2014-2019)
Figure 2018 European Union Biosimilars Insulin Market Share by Application
Figure China Biosimilars Insulin Sales Growth Rate 2014-2019 (K MT)
Figure China Biosimilars Insulin Revenue Growth Rate 2014-2019 (Million US$)
Table China Biosimilars Insulin Sales by Company (2014-2019) (K MT)
Table China Biosimilars Insulin Sales Market Share by Company (2014-2019)
Figure China Biosimilars Insulin Sales Market Share by Company in 2019
Table China Biosimilars Insulin Sales by Type (2014-2019) (K MT)
Table China Biosimilars Insulin Sales Market Share by Type (2014-2019)
Figure China Biosimilars Insulin Market Share by Type in 2019
Table China Biosimilars Insulin Sales by Application (2014-2019) (K MT)
Table China Biosimilars Insulin Sales Market Share by Application (2014-2019)
Figure China Biosimilars Insulin Market Share by Application in 2019
Figure Rest of World Biosimilars Insulin Sales Growth Rate 2014-2019 (K MT)
Figure Rest of World Biosimilars Insulin Revenue Growth Rate 2014-2019 (Million US$)
Table Rest of World Biosimilars Insulin Sales by Company (2014-2019) (K MT)
Table Rest of World Biosimilars Insulin Sales Market Share by Company (2014-2019)
Figure Rest of World Biosimilars Insulin Sales Market Share by Company in 2019
Table Rest of World Biosimilars Insulin Sales by Type (2014-2019) (K MT)
Table Rest of World Biosimilars Insulin Sales Market Share by Type (2014-2019)
Figure Rest of World Biosimilars Insulin Market Share by Type in 2019
Table Rest of World Biosimilars Insulin Sales by Application (2014-2019) (K MT)
Table Rest of World Biosimilars Insulin Sales Market Share by Application (2014-2019)
Figure Rest of World Biosimilars Insulin Market Share by Application in 2019
Table Rest of World Biosimilars Insulin Sales by Countries (2014-2019) (K MT)
Table Rest of World Biosimilars Insulin Sales Market Share by Countries (2014-2019)
Figure Rest of World Biosimilars Insulin Sales Market Share by Countries in 2019
Table Rest of World Biosimilars Insulin Revenue by Countries (2014-2019) (Million US$)
Table Rest of World Biosimilars Insulin Revenue Market Share by Countries (2014-2019)
Figure Rest of World Biosimilars Insulin Revenue Market Share by Countries in 2019
Figure Japan Biosimilars Insulin Sales Growth Rate (2014-2019) (K MT)
Figure Japan Biosimilars Insulin Revenue Growth Rate (2014-2019) (K MT)
Figure Korea Biosimilars Insulin Sales Growth Rate (2014-2019) (K MT)
Figure Korea Biosimilars Insulin Revenue Growth Rate (2014-2019) (K MT)
Figure India Biosimilars Insulin Sales Growth Rate (2014-2019) (K MT)
Figure India Biosimilars Insulin Revenue Growth Rate (2014-2019) (K MT)
Figure Southeast Asia Biosimilars Insulin Sales Growth Rate (2014-2019) (K MT)
Figure Southeast Asia Biosimilars Insulin Revenue Growth Rate (2014-2019) (K MT)
Table Eli Lilly Company Details
Table Eli Lilly Description and Business Overview
Table Eli Lilly Biosimilars Insulin Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2014-2019)
Table Eli Lilly Biosimilars Insulin Sales Growth Rate (2014-2019)
Table Eli Lilly Biosimilars Insulin Sales Market Share in Global Market
Table Eli Lilly Recent Development
Table Boehringer Ingelheim Company Details
Table Boehringer Ingelheim Description and Business Overview
Table Boehringer Ingelheim Biosimilars Insulin Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2014-2019)
Table Boehringer Ingelheim Biosimilars Insulin Sales Growth Rate (2014-2019)
Table Boehringer Ingelheim Biosimilars Insulin Sales Market Share in Global Market
Table Boehringer Ingelheim Recent Development
Table Merck Company Details
Table Merck Description and Business Overview
Table Merck Biosimilars Insulin Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2014-2019)
Table Merck Biosimilars Insulin Sales Growth Rate (2014-2019)
Table Merck Biosimilars Insulin Sales Market Share in Global Market
Table Merck Recent Development
Table Pfizer Company Details
Table Pfizer Description and Business Overview
Table Pfizer Biosimilars Insulin Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2014-2019)
Table Pfizer Biosimilars Insulin Sales Growth Rate (2014-2019)
Table Pfizer Biosimilars Insulin Sales Market Share in Global Market
Table Pfizer Recent Development
Table Biocon Company Details
Table Biocon Description and Business Overview
Table Biocon Biosimilars Insulin Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2014-2019)
Table Biocon Biosimilars Insulin Sales Growth Rate (2014-2019)
Table Biocon Biosimilars Insulin Sales Market Share in Global Market
Table Biocon Recent Development
Table Mylan Company Details
Table Mylan Description and Business Overview
Table Mylan Biosimilars Insulin Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2014-2019)
Table Mylan Biosimilars Insulin Sales Growth Rate (2014-2019)
Table Mylan Biosimilars Insulin Sales Market Share in Global Market
Table Mylan Recent Development
Figure Biosimilars Insulin Value Chain
Table Biosimilars Insulin Distributors List
Table Biosimilars Insulin Customers List
Table Global Biosimilars Insulin Sales Forecast 2019-2025 (K MT) & (Million US$)
Figure Global Biosimilars Insulin Sales Forecast 2019-2025 (K MT)
Figure Global Biosimilars Insulin Revenue Forecast 2019-2025 (Million US$)
Table Global Biosimilars Insulin Sales Forecast by Type 2019-2025 (K MT)
Figure Global Biosimilars Insulin Sales Forecast by Type 2019-2025 (K MT)
Figure Global Biosimilars Insulin Sales Market Share Forecast by Type 2019-2025
Table Global Biosimilars Insulin Sales Forecast by Application 2019-2025 (K MT)
Figure Global Biosimilars Insulin Sales Forecast by Application 2019-2025 (K MT)
Figure Global Biosimilars Insulin Sales Market Share Forecast by Application 2019-2025
Table Global Biosimilars Insulin Sales Forecast by Regions 2019-2025 (K MT)
Figure Global Biosimilars Insulin Sales Forecast by Regions 2019-2025 (K MT)
Figure Global Biosimilars Insulin Sales Market Share Forecast by Regions 2019-2025
Table Global Biosimilars Insulin Revenue Forecast by Regions 2019-2025 (K MT)
Figure Global Biosimilars Insulin Revenue Forecast by Regions 2019-2025 (K MT)
Figure Global Biosimilars Insulin Revenue Market Share Forecast by Regions 2019-2025
Figure United States Biosimilars Insulin Sales Forecast 2019-2025 (K MT)
Figure United States Biosimilars Insulin Revenue Forecast 2019-2025 (Million US$)
Figure European Union Biosimilars Insulin Sales Forecast 2019-2025 (K MT)
Figure European Union Biosimilars Insulin Revenue Forecast 2019-2025 (Million US$)
Figure China Biosimilars Insulin Sales Forecast 2019-2025 (K MT)
Figure China Biosimilars Insulin Revenue Forecast 2019-2025 (Million US$)
Figure Japan Biosimilars Insulin Sales Forecast 2019-2025 (K MT)
Figure Japan Biosimilars Insulin Revenue Forecast 2019-2025 (Million US$)
Figure Korea Biosimilars Insulin Sales Forecast 2019-2025 (K MT)
Figure Korea Biosimilars Insulin Revenue Forecast 2019-2025 (Million US$)
Figure India Biosimilars Insulin Sales Forecast 2019-2025 (K MT)
Figure India Biosimilars Insulin Revenue Forecast 2019-2025 (Million US$)
Figure Southeast Asia Biosimilars Insulin Sales Forecast 2019-2025 (K MT)
Figure Southeast Asia Biosimilars Insulin Revenue Forecast 2019-2025 (Million US$)
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources
